Beryl Drugs Peer Comparison

BSE: 524606

₹23.99

₹0.22 (0.93%)

As on 23-Sep-2026 14:28IST

Market cap

₹12 Cr

Revenue (TTM)

₹22 Cr

P/E Ratio

19.5

P/B Ratio

1.2

Div. Yield

0 %

Edit

	Beryl Drugs	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Market cap (₹ Cr)	12	37,544	27,726	26,649	27,952
Revenue (₹ Cr)	22	3,564	1,936	1,462	9,205
Net Profit (₹ Cr)	0.62	414.00	288.22	387.35	-371.81
Net Margin (%)	2.83	11.23	14.79	26.01	-3.93
RoE (%)	6.45	8.38	29.77	25.18	-3.85
Price to Earnings	19.50	91.79	96.20	69.00	--
Price-To-Book	1.21	7.46	20.66	15.44	3.49

Income Statement (₹ Cr)

	Beryl Drugs	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Operating Revenue	22.04	3,564.00	1,935.80	1,461.80	9,205.28
Total Income	22.04	3,686.00	1,948.58	1,489.25	9,449.59
Total Expenditure	19.52	2,792.00	1,485.56	919.25	8,195.15
EBITDA	2.52	772.00	450.24	542.56	1,010.13
Depreciation	1.43	226.00	50.83	37.68	857.51
EBIT	1.09	546.00	399.41	504.88	152.62
Interest	0.31	217.00	40.84	3.77	342.73
Other Income	0.00	122.00	12.78	27.45	244.31
Exceptional Items	0.00	12.00	0.00	0.00	-216.88
Profit before Tax	0.79	463.00	371.35	528.56	-162.68
Provision for Tax	0.16	49.00	83.14	141.21	209.13
Profit after Tax	0.62	414.00	288.22	387.35	-371.81

	Beryl Drugs	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Shareholder's Funds	9.89	4,940.00	1,288.82	1,653.56	8,162.62
Minority Interest	0.00	-5.00	0.00	-1.13	0.00
Non-Current Liabilities	0.60	1,712.00	202.03	42.40	5,044.14
Current Liabilities	4.48	1,622.00	835.87	230.82	4,758.28
Total Liabilities	16.04	8,100.00	1,451.43	1,549.26	15,513.53

	Beryl Drugs	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Non-Current Assets	6.76	5,343.00	519.60	1,026.85	10,211.52
Current Assets	6.83	2,606.00	1,681.81	881.27	7,191.66
Total Assets	16.04	8,100.00	1,451.43	1,549.26	15,513.53
Total Debt*	4.07	1,859.00	393.17	8.18	4,720.27
Net Current Assets	2.35	984.00	845.94	650.46	2,433.38
Contingent Liabilities	--	770.26	12.25	15.38	99.76

	Beryl Drugs	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Cash From Operating Activities	2.64	-22.00	159.18	118.34	892.30
Cash Flow from Investing Activities	-0.40	-783.00	-64.81	-223.94	-477.46
Cash from Financing Activities	-1.55	409.00	-39.81	261.12	-440.83
Net Cash Inflow / Outflow	0.69	-396.00	54.56	155.52	-25.99

	Beryl Drugs	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
ROCE (%)	10.15	4.07	26.97	20.14	6.61
ROE (%)	6.45	8.38	29.77	25.18	-3.85
ROA (%)	4.04	4.94	24.77	21.93	-2.21
EBIT Margin (%)	4.96	15.32	20.63	34.54	1.66
Net Margin (%)	2.83	11.23	14.79	26.01	-3.93
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

	Beryl Drugs	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Revenue Growth (%)	4.44	18.37	46.65	40.90	0.78
EBIT Growth (%)	27.09	252.26	62.13	124.50	-70.53
Net Profit Growth (%)	172.49	377.85	89.49	104.15	-1,383.43
EPS Growth (%)	172.49	1,001.33	78.60	42.32	-484.84
Book Value Growth (%)	6.52	29.77	42.49	94.96	2.28

	Beryl Drugs	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Price / Earnings	19.32	89.10	94.55	68.11	-89.41
Price / Book Value	1.20	7.05	20.62	15.25	3.50
Dividend Yield (%)	0.00	0.00	0.09	0.08	0.00
EV/EBITDA	6.07	47.88	61.28	48.12	31.80
Market Cap (₹ Cr)	10.68	23,064.69	0.00	19,988.69	29,731.27

	Beryl Drugs	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Debt to Equity	0.00	0.31	0.11	0.01	0.53
Short term debt to equity ratio	0.25	0.11	0.54	0.02	0.12
Current Ratio	1.52	1.61	2.01	3.82	1.51
Quick Ratio	0.83	1.06	1.14	2.82	0.87
Interest Coverage	3.57	3.13	10.09	141.16	0.53

	Beryl Drugs	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Debtors to sales (%)	9.47	16.50	26.28	24.80	23.44
Asset Turnover	1.43	0.43	1.66	0.83	0.55
Receivable days	112.55	60.36	47.59	90.06	77.05
Inventory Days	27.30	64.42	62.58	61.02	77.13
Payable days	729.63	218.94	228.78	96.06	173.49
Cash Conversion Cycle	-589.78	-94.15	-118.62	55.02	-19.30

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.